All News about Regeneron Pharmaceuticals
Via GlobeNewswire
Via Benzinga
Via Benzinga
Via Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
Topics
Economy
Exposures
Interest Rates
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
Via Benzinga
Topics
Fraud
Exposures
Legal
Via GlobeNewswire
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
Via Benzinga
Exposures
Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.